FIG. 7.

Parkin is required for statin-mediated cardioprotection which is abolished by coenzyme Q₁₀. (A) Area-at-risk of wild-type versus Parkin knockout mice (PKO) treated either with either vehicle (DMSO, solid bars), or simvastatin (statin, hashed bars). (B) Quantitation of infarct size as a percentage of risk area. Treatment groups identified as: vehicle (DMSO, solid diamonds) and simvastatin (statin, open diamonds). Individual diamonds signify the result for each mouse heart. n=4–6 mice per group. *p-value<0.01. (C) Area-at-risk of wild-type mice treated either with either vehicle control (DMSO, solid bars), or simvastatin (statin, hashed bars), followed 1 h later with 10 mg/kg coenzyme Q₁₀ i.p. Coronary artery ligation was performed 4 h after statin administration and infarct size was determined 22 h later. (D) Quantitation of infarct size as a percentage of risk area from (C). Treatment groups identified as: vehicle (DMSO, solid diamonds) and simvastatin (statin, open diamonds). Individual diamonds signify the result for each mouse. n=4–6 mice per group. *p-value<0.05.